Novo Nordisk shares trade flat at $44.535 on Wegovy China approval
Novo Nordisk shares were quoted at $44.535 and stayed flat on Thursday morning. China cleared Wegovy for metabolic dysfunction-associated steatohepatitis (MASH), described as the first approved GLP-1 receptor agonist in China.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.